The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index; 15 of the 21 sources its claims cite were checked for support.
The Synergistic Effect of Proanthocyanidin and HDAC Inhibitor Inhibit Breast Cancer Cell Growth and Promote Apoptosis
Open accessAbstract
Histone deacetylase inhibitor (HDACi) is a drug mainly used to treat hematological tumors and breast cancer, but its inhibitory effect on breast cancer falls short of expectations. Grape seed proanthocyanidin extract (GSPE) with abundant proanthocyanidins (PAs) has been explored for its inhibition of HDAC activity in vitro and in vivo. To enhance HDACi's effectiveness, we investigated the potential of PA to synergistically enhance HDACi chidamide (Chi), and determined the underlying mechanism. We evaluated the half-inhibitory concentration (IC50) of PA and Chi using the cell counting kit 8 (CCK8), and analyzed drugs' synergistic effect with fixed-ratio combination using the software Compusyn. Breast cancer cell's phenotypes, including short-term and long-term proliferation, migration, invasion, apoptosis, and reactive oxygen species (ROS) levels, were assessed via CCK8, clone-formation assay, wound-healing test, Transwell Matrigel invasion assay, and flow-cytometry. Protein-protein interaction analysis (PPI) and KEGG pathway analysis were used to determine the underlying mechanism of synergy. PA + Chi synergistically inhibited cell growth in T47D and MDA-MB-231 breast cancer cell lines. Short-term and long-term proliferation were significantly inhibited, while cell apoptosis was promoted. Ten signaling pathways were identified to account for the synergistic effect after RNA sequencing. Their synergism may be closely related to the steroid biosynthesis and extracellular matrix (ECM) receptor interaction pathways. PA + Chi can synergistically inhibit breast cancer cell growth and proliferation, and promote apoptosis. These effects may be related to steroid biosynthesis or the ECM receptor pathway.
Overview
CoChat Summary
TL;DR
Proanthocyanidin (PA) combined with the HDAC inhibitor chidamide (Chi) synergistically inhibited breast cancer cell growth and proliferation and promoted apoptosis in T47D and MDA-MB-231 cells. The synergy was associated with steroid biosynthesis and ECM receptor interaction pathways.
Key findings
- PA + Chi showed synergistic growth inhibition in T47D at an 18.5:1 ratio and in MDA-MB-231 at a 50:1 ratio; IC50 values were PA 90.74 µg/mL and Chi 9.778 µM in T47D, and PA 87.9 µg/mL and Chi 3.096 µM in MDA-MB-231.
- Clone formation was significantly reduced by PA + Chi (133 ± 40 colonies) versus control (467 ± 92), PA (386 ± 100), and Chi (806 ± 131) (all p < 0.05).
- Apoptosis was increased by PA + Chi: 14.9% early and 31.8% late apoptosis, versus control 6.39% early and 12.0% late, PA 4.68% early and 10.9% late, and Chi 4.3% early and 20.8% late.
- RNA sequencing identified 247 potentially synergistic DEGs after excluding 187 shared PA/Chi genes; KEGG analysis found 21 pathways with nominal p < 0.05, and PPI highlighted steroid biosynthesis and ECM receptor interaction as most promising.
Methods
- T47D and MDA-MB-231 breast cancer cell lines were used; ER+ cell line selection was based on HDAC1/2/3/10 expression from GEO single-cell RNA-seq dataset GSE173634.
- Drug effects were assessed by CCK8 IC50, Compusyn fixed-ratio synergy analysis, short-term proliferation, clone formation, wound healing, Transwell Matrigel invasion, Annexin V-FITC/PI apoptosis flow cytometry, and DHE ROS flow cytometry.
- Transcriptome sequencing used 12 T47D samples across four groups with three replicates; DEGs were called at FDR < 0.05 and FC ± 2, followed by KEGG pathway annotation and STRING PPI analysis; statistics used one-way ANOVA with p < 0.05.
Limitations
- The paper states that the entire pathway and specific genes involved in the synergistic effect were not confirmed, and that post-transcriptional regulation by HDACi was not addressed; shRNA interference and in vivo experiments are warranted.
- Evident from the text: all reported experiments are in vitro, using T47D and MDA-MB-231 cells, with no in vivo validation reported.
- Evident from the text: the mechanistic conclusion relies on transcriptome sequencing and bioinformatic enrichment/PPI rather than direct functional validation of steroid biosynthesis or ECM receptor pathways.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
7 Valid · 1 Not valid · 1 Not checked · 40 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous studies have reported that GSPE regulates histone acetylation and decreases HDAC activity in both in vivo and in vitro settings, whether used individually or in combination [23,25].”
§ The Synergistic Effect of Proanthocyanidin and HDAC Inhibitor Inhibit Breast Cancer Cell Growth and Promote Apoptosis > 1. Introduction
What the sources say
- Partly supportedcites [23] Gao, Y., and Tollefsbol, T.O. (2018). Combinational Proanthocyanidins and Resveratrol Synergistically Inhibit Human Breast Cancer Cells and Impact Epigenetic-Mediating Machinery. Int. J. Mol. Sci., 19. sourceExperimental — accuracy not yet measured
Results §2.5 reports that grape seed proanthocyanidins, alone and combined with resveratrol, decreased HDAC activity in two cultured human breast cancer cell lines. The paper does not report an in vivo HDAC result or a direct measurement of histone acetylation, so those parts of the claim are unsupported by this source. (LLM, conf=0.88)
- Partly supportedcites [25] Downing, 2017, A grape seed procyanidin extract inhibits HDAC activity leading to increased Pparα phosphorylation and target-gene expression, Mol. Nutr. Food Res. sourceExperimental — accuracy not yet measured
Section 3.1 (page not supplied) reports increased histone acetylation and reduced Class I HDAC activity in GSPE-treated mouse liver, as well as HDAC inhibition in vitro. It does not report histone acetylation in vitro or test GSPE in combination with another treatment, so those parts of the citing sentence are not supported by this paper. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Combining PAs with other drugs can also enhance the effects of the other drugs [23,24].”
§ The Synergistic Effect of Proanthocyanidin and HDAC Inhibitor Inhibit Breast Cancer Cell Growth and Promote Apoptosis > 1. Introduction
What the sources say
- Partly supportedcites [23] Gao, Y., and Tollefsbol, T.O. (2018). Combinational Proanthocyanidins and Resveratrol Synergistically Inhibit Human Breast Cancer Cells and Impact Epigenetic-Mediating Machinery. Int. J. Mol. Sci., 19. sourceExperimental — accuracy not yet measured
The Results (§2.1; page unavailable) report that grape seed proanthocyanidins combined with resveratrol reduced viability in two human breast cancer cell lines more than either compound alone. This supports an enhanced effect for that specific combination, but not the broader claim about combining proanthocyanidins with other drugs generally; the paper describes resveratrol as a polyphenol. (LLM, conf=0.86)
- Supportedcites [24] Carriere, 2018, Cinnamtannin B-1 inhibits cell survival molecules and induces apoptosis in colon cancer, Int. J. Oncol. source
The Results section reports that cinnamtannin B-1 (CTB-1), a proanthocyanidin, enhanced the potency of 5-fluorouracil against colon cancer cells in vitro. The Discussion describes a nearly 3–4-fold increase in 5-fluorouracil potency through synergistic interactions. The claim says this can happen, which this example supports; the paper does not establish that it happens with all proanthocyanidins or drugs. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous research has demonstrated the inhibitory effect of PAs on lipid metabolism and the expression of steroid metabolism-related enzymes, which can suppress breast cancer carcinogenesis [30,31,32].”
§ The Synergistic Effect of Proanthocyanidin and HDAC Inhibitor Inhibit Breast Cancer Cell Growth and Promote Apoptosis > 3. Discussion
What the sources say
- Not checked — no full text of the sourcecites [30] Zhou, 2018, Anti-atherosclerosis of oligomeric proanthocyanidins from Rhodiola rosea on rat model via hypolipemic, antioxidant, anti-inflammatory activities together with regulation of endothelial function, Phytomedicine source
- Not checked — no full text of the sourcecites [31] Shi, 2019, miR-96 and autophagy are involved in the beneficial effect of grape seed proanthocyanidins against high-fat-diet-induced dyslipidemia in mice, Phytother. Res. source
- Partly supportedcites [32] Song, 2010, Grape seed proanthocyanidin suppression of breast cell carcinogenesis induced by chronic exposure to combined 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene, Mol. Carcinog. sourceExperimental — accuracy not yet measured
The Results (Molecular Target Endpoint for GSPE in Suppression of Carcinogenesis; page unavailable) report that grape seed proanthocyanidin extract reduced expression of HSD11B2, a steroid-metabolizing enzyme, in carcinogen-exposed breast cells. The Discussion reports suppression of precancerous cellular properties. The paper does not report inhibition of lipid metabolism, and its findings concern precancerous cells rather than demonstrated prevention of breast cancer. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The results showed that cell proliferation rate in the PA + Chi group was lower than in the PA or Chi treatment groups.”
§ The Synergistic Effect of Proanthocyanidin and HDAC Inhibitor Inhibit Breast Cancer Cell Growth and Promote Apoptosis > 2. Results > 2.2. Analysis of the Cell Function of Proanthocyanidin in the Synergistic HDACi Inhibition of Breast Cancer Cell Growth
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, there was no significant difference in ROS levels between the two groups (Figure 2f)”
§ The Synergistic Effect of Proanthocyanidin and HDAC Inhibitor Inhibit Breast Cancer Cell Growth and Promote Apoptosis > 2. Results > 2.2. Analysis of the Cell Function of Proanthocyanidin in the Synergistic HDACi Inhibition of Breast Cancer Cell Growth
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
30 more claims
Create a free account to see all 49 claims and every source verdict.
- It may state two separate claims as one. 11
- Probably not a substantial claim. 4
Citations
Cites
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163 · cited 1×
“0), which is a simple computerized analytical simulation based on the median-effect principle of the mass-action law and its combination index theorem [34].”
MethodGreen tea composition, consumption, and polyphenol chemistry
Graham, H. N. (1992) · Preventive Medicine · doi:10.1016/0091-7435(92)90041-f · Cited by 1,881
Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase
Nagy, L., Kao, H.-Y., Chakravarti, D., Lin, R. J., Hassig, C. A., Ayer, D. E., Schreiber, S. L., & Evans, R. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80218-4 · Cited by 1,230
Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer
Snaebjornsson, M. T., Janaki-Raman, S., & Schulze, A. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.010 · Cited by 1,097
Kim, Y. H., Bagot, M., Pinter-Brown, L., Rook, A. H., Porcu, P., Horwitz, S. M., Whittaker, S., Tokura, Y., Vermeer, M., Zinzani, P. L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30379-6 · Cited by 669 · cited 1×
“However, the clinical application of HDACi as a therapy for breast cancer is limited due to frequent toxicity and adverse effects, including those involving the blood, lymphatic, and gastrointestinal systems [26].”
BackgroundMechanisms of tamoxifen resistance
Ring, A., & Dowsett, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00776 · Cited by 651 · cited 1×
“Approximately 70% of breast cancer cases are estrogenreceptor-positive (ER+), but many patients develop primary or secondary resistance to hormone therapy [2,3].”
BackgroundGu, L., Kelm, M. A., Hammerstone, J. F., Beecher, G., Holden, J., Haytowitz, D., & Prior, R. L. (2003) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf034815d · Cited by 617
Phenolic Content and Antioxidant Capacity of Muscadine Grapes
Pastrana-Bonilla, E., Akoh, C. C., Sellappan, S., & Krewer, G. (2003) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf030113c · Cited by 521
(2003) · PubMed · Cited by 465
Hong, L., Schroth, G. P., Matthews, H. R., Yau, P., & Bradbury, E. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54150-8 · Cited by 432
Cited by
Uniyal, P., Akhtar, A., & Rawat, R. (2025) · Pharmaceuticals · doi:10.3390/ph18101486 · Cited by 26
“[ Suppress the growth and proliferation, while promoting apoptosis [220] 5-Fluorouracil MDA-MB-231 Cell viability and migration declined, apoptosis was induced, cell cycle was arrested in the G2/M phase, generated ROS was increased, mitochondrial membrane potential reduced, the Bax/Bcl-2 ratio was…”
Tiwari, H., Singh, S., Sharma, S., Gupta, P., Verma, A. K., Chattopadhaya, A., Kumar, B., Agarwal, S., Kumar, R., Gupta, S., et al. (2024) · Medicinal Research Reviews · doi:10.1002/med.22090 · Cited by 22
Zhou, J.-B., Li, C., Qian, L., & Chu, J.-H. (2025) · Computer Methods in Biomechanics & Biomedical Engineering · doi:10.1080/10255842.2025.2495299 · Cited by 5
“Subsequently, Xu et al. reported that ADAM12 could promote ccRCC progression through activating EGFR/ERK signaling pathway (Xu et al. 2023).”
Luo, H., Sun, Y., & Xu, T. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1513836 · Cited by 5
(2023) · doi:10.1155/2023/9910431 · Cited by 4
“In order to further understand the metabolic pathways and specifc biological functions of DEGs, OmicShare tools were used for KEGG enrichment analysis [19].”
Method
Metadata
- Authors
- Wang, T. K., Xu, S., Fan, Y., Wu, J., Wang, Z., Chen, Y., & Zhang, Y.
- Affiliations
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Corresponding author
- Zhang, Yunjian
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-06-22
- Volume
- 24
- Issue
- 13
- Pages
- 10476
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10341808
- OpenAlex
- W4381617893
- Cited by
- 18
- References
- 35
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 3 · 2023: 1
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81872344)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Biochemistry (medical) › Phytochemicals and Antioxidant Activities
- Keywords
- proanthocyanidins, grape seed proanthocyanidin extract, histone deacetylase inhibitors, chidamide, synergistic drug combination, breast cancer, apoptosis, cell proliferation, cell migration and invasion, reactive oxygen species, steroidogenesis, T47D cells, MDA-MB-231 cells
- MeSH terms
- Neoplasms, Steroids, Apoptosis, Proanthocyanidins, Cell Line, Tumor, Cell Proliferation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Synergistic Effect of Proanthocyanidin and HDAC Inhibitor Inhibit Breast Cancer Cell Growth and Promote Apoptosis. https://app.cochat.ai/papers/10.3390/ijms241310476
- The paper
- Wang, T. K., Xu, S., Fan, Y., Wu, J., Wang, Z., Chen, Y., & Zhang, Y. (2023). The Synergistic Effect of Proanthocyanidin and HDAC Inhibitor Inhibit Breast Cancer Cell Growth and Promote Apoptosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241310476
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.